Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors

키워드

참고문헌 (141)

1. Larkin J, "Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373, pp.23~34 (2015)
2. Ishida Y, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
3. Selvakumar A, "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7", Immunogenetics, 36, pp.175~181 (1992)
4. Karre K, "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy", Nature, 319, pp.675~678 (1986)
5. Kim S, "Licensing of natural killer cells by host major histocompatibility complex class I molecules", Nature, 436, pp.709~713 (2005)
6. Kim S, "HLA alleles determine differences in human natural killer cell responsiveness and potency", Proc Natl Acad Sci U S A, 105, pp.3053~3058 (2008)
7. Djaoud Z, "HLAs, TCRs, and KIRs, a triumvirate of human cell-mediated immunity", Annu Rev Biochem, 89, pp.717~739 (2020)
8. Saunders PM, "A bird’s eye view of NK cell receptor interactions with their MHC class I ligands", Immunol Rev, 267, pp.148~166 (2015)
9. Benson DM Jr., "A phase 1 trial of the anti-KIR antibody IPH2101in patients with relapsed", refractory multiple myeloma, 2012, pp.120, 4324~4333
10. Vey N, "A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission", Blood, 120, pp.4317~4323 (2012)
11. Carlsten M, "Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma", Clin Cancer Res, 22, pp.5211~5222 (2016)
12. Benson DM Jr, "A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed", refractory multiple myeloma, 2015, pp.21, 4055~4061
13. Kohrt HE, "Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies", Blood, 123, pp.678~686 (2014)
14. Yalniz FF, "A pilot trial of Lirilumab with or without Azacitidine for patients with myelodysplastic syndrome", Clin Lymphoma Myeloma Leuk, 18, pp.658~663 (2018)
15. Binyamin L, "Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy", J Immunol, 180, pp.6392~6401 (2008)
16. Bagot M, "IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma : an international, first-in-human, openlabel, phase 1 trial", Lancet Oncol, 20, pp.1160~1170 (2019)
17. Ewen EM, "KIR downregulation by IL-12", 15, HLA-I inhibition and enhances killing of tumor cells, pp.Eur J Immunol, 2018[DOI]
18. Shiroishi M, "Human inhibitory receptors Ig-like transcript 2(ILT2)and ILT4compete with CD8 for MHC class I binding and bind preferentially to HLA-G", Proc Natl Acad Sci U S A, 100, pp.8856~8861 (2003)
19. Khan M, "NK cell-based immune checkpoint inhibition", Front Immunol, 11, pp.167~ (2020)
20. Scarabel L, "Soluble HLA-G expression levels and HLA-G", irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy, 2020, pp.10, 8773~
21. Bertol BC, "Plasma levels of soluble HLA-G and cytokines in papillary thyroid carcinoma before and after thyroidectomy", Int J Clin Pract, 74, pp.e13585~ (2020)
22. Heidenreich S, "Impact of the NK cell receptor LIR-1(ILT-2", CD85j, Clin Dev Immunol, pp.2012, 2012[DOI]
23. Godal R, "Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade", Biol Blood Marrow Transplant, 16, pp.612~621 (2010)
24. Ho GT, "NKG2A", CD94is a new immune receptor for HLA-G and distinguishes amino acid differences in the HLA-G heavy chain, 2020, pp.21, 4362~
25. Burshtyn DN, "Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor", Immunity, 4, pp.77~85 (1996)
26. Olcese L, "Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases", J Immunol, 156, pp.4531~4534 (1996)
27. Stebbins CC, "Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity", Mol Cell Biol, 23, pp.6291~6299 (2003)
28. Liu D, "The adaptor protein Crk controls activation and inhibition of natural killer cells", Immunity, 36, pp.600~611 (2012)
29. Long EO, "Controlling natural killer cell responses : integration of signals for activation and inhibition", Annu Rev Immunol, 31, pp.227~258 (2013)
30. Levy EM, "Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer", Int J Oncol, 32, pp.633~641 (2008)
31. Gooden M, "HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+)T lymphocytes", Proc Natl Acad Sci U S A, 108, pp.10656~10661 (2011)
32. Della Chiesa M, "Features of memory-like and PD-1(+)human NK cell subsets", Front Immunol, 7, pp.351~ (2016)
33. McWilliams EM, "Therapeutic CD94", NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia, 2016, pp.5, e1226720~
34. Chiossone L, "Natural killer cell immunotherapies against cancer : checkpoint inhibitors and more", Semin Immunol, 31, pp.55~63 (2017)
35. Burugu S, "Emerging targets in cancer immunotherapy", Semin Cancer Biol, 52, pp.39~52 (2018)
36. Andre P, "Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells", Cell, 175, pp.1731~1743 (2018)
37. van Montfoort N, "NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines", Cell, 175, pp.1744~1755 (2018)
38. Schildberg FA, "Coinhibitory pathways in the B7-CD28 ligandreceptor family", Immunity, 44, pp.955~972 (2016)
39. Stojanovic A, "CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-gamma production in response to mature dendritic cells", J Immunol (2014)
40. Jie HB, "CTLA-4(+)regulatory T cells increased in Cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis", Cancer Res, 75, pp.2200~2210 (2015)
41. Romano E, "Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients", Proc Natl Acad Sci U S A, 112, pp.6140~6145 (2015)
42. Simpson TR, "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", J Exp Med, 210, pp.1695~1710 (2013)
43. Tallerico R, "IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients", Oncoimmunology, 6, pp.e1261242~ (2017)
44. Jallad MN, "Triple immunotherapy overcomes immune evasion by tumor in a melanoma mouse model", Front Oncol, 10, pp.839~ (2020)
45. Lang S, "Absence of B7. 1-CD28", CTLA-4-mediated co-stimulation in human NK cells, 1998, pp.28, 780~786
46. Cook CH, "CD28", B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection, 2009, pp.22, 91~103
47. Boussiotis VA, "Biochemical signaling of PD-1 on T cells and its functional implications", Cancer J, 20, pp.265~271 (2014)
48. Pesce S, "Identification of a subset of human natural killer cells expressing high levels of programmed death 1 : a phenotypic and functional characterization", J Allergy Clin Immunol, 139, pp.335~346 (2017)
49. Tabellini G, "Primitive neuroectodermal tumor in an ovarian cystic teratoma : natural killer and neuroblastoma cell analysis", Case Rep Oncol, 7, pp.70~78 (2014)
50. Beldi-Ferchiou A, "PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma", Oncotarget, 7, pp.72961~72977 (2016)
51. Benson DM Jr, "The PD-1", PD-L1 axis modulates the natural killer cell versus multiple myeloma effect : a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, 2010, pp.116, 2286~2294
52. Vari F, "Immune evasion via PD-1", PD-L1 on NK cells and monocyte, Blood, pp.2018, 131[DOI]
53. Hsu J, "Contribution of NK cells to immunotherapy mediated by PD-1", PD-L1blockade, 2018, pp.128, 4654~4668
54. Lanuza PM, "Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression", Oncoimmunology, 7, pp.e1395123~ (2018)
55. Hwang S, "Cytotoxicity of human hepatic intrasinusoidal CD56(bright)natural killer cells against hepatocellular carcinoma cells", Int J Mol Sci, 20, pp.1564~ (2019)
56. Judge SJ, "Minimal PD-1expression in mouse and human NK cells under diverse conditions", J Clin Invest, 130, pp.3051~3068 (2020)
57. Quatrini L, "Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells", Nat Immunol, 19, pp.954~962 (2018)
58. Anderson AC, "Lag-3, Tim-3, and TIGIT : co-inhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
59. Rangachari M, "Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion", Nat Med, 18, pp.1394~1400 (2012)
60. Carotta S, "Targeting NK cells for anticancer immunotherapy : clinical and preclinical approaches", Front Immunol, 7, pp.152~ (2016)
61. Wang Z, "The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer", Immunol Invest, 44, pp.578~589 (2015)
62. Xu L, "Increased Tim-3expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma", Int Immunopharmacol, 29, pp.635~641 (2015)
63. Komita H, "Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3", galectin-9 for NK cell suppression in human gastrointestinal stromal tumors, 2015, pp.34, 2099~2105
64. Gallois A, "Reversal of natural killer cell exhaustion by TIM-3 blockade", Oncoimmunology, 3, pp.e946365~ (2014)
65. Zhang C, "Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy", Front Immunol, 11, pp.1295~ (2020)
66. Chauhan SKS, "Harnessing NK cell checkpoint-modulating immunotherapies", Cancers (Basel), 12, pp.1807~ (2020)
67. Van Audenaerde JRM, "Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells", Oncotarget, 8, pp.56968~56979 (2017)
68. Folgiero V, "TIM-3", Gal-9 interaction induces IFN gamma-dependent IDO1 expression in acute myeloid leukemia blast cells, 2015, pp.8, 36~
69. Markel G, "The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells", J Immunol, 173, pp.3732~3739 (2004)
70. Fantini M, "The monoclonal antibody NEO-201 enhances natural killer cell cytotoxicity against tumor cells through blockade of the inhibitory CEACAM5", CEACAM1 immune checkpoint pathway, 2020, pp.35, 190~198
71. Zeligs KP, "Evaluation of the anti-tumor activity of the humanized monoclonal antibody NEO-201 in preclinical models of ovarian cancer", Front Oncol, 10, pp.805~ (2020)
72. Jacques A, "A synergistic interferon-gamma production is induced by mouse hepatitis virus in interleukin-12(IL-12)", IL-18-activated natural killer cells and modulated by carcinoembryonic antigen-related cell adhesion molecules(CEACAM)1a receptor, 2009, pp.128, e551~e561
73. Hosomi S, "CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling", Eur J Immunol, 43, pp.2473~2483 (2013)
74. Kim WM, "CEACAM1 structure and function in immunity and its therapeutic implications", Semin Immunol, 42, pp.101296~ (2019)
75. Zhang Q, "Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity", Nat Immunol, 19, pp.723~732 (2018)
76. Johnston RJ, "The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+)T cell effector function", Cancer Cell, 26, pp.923~937 (2014)
77. Gorvel L, "Targeting the"PVR-TIGIT axis"with immune checkpoint therapies", F1000Res, 9, pp.354~ (2020)
78. Wang J, "Fibrinogenlike protein 1 is a major immune inhibitory ligand of LAG-3", Cell, 176, pp.334~347 (2019)
79. Maeda TK, "Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3inhibit T cell activation", J Biol Chem, 294, pp.6017~6026 (2019)
80. Merino A, "Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming", J Clin Invest, 129, pp.3770~3785 (2019)
81. Brignone C, "A soluble form of lymphocyte activation gene-3(IMP321)induces activation of a large range of human effector cytotoxic cells", J Immunol, 179, pp.4202~4211 (2007)
82. Brignone C, "A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma", Clin Cancer Res, 15, pp.6225~6231 (2009)
83. Brignone C, "First-line chemoimmunotherapy in metastatic breast carcinoma : combination of paclitaxel and IMP321(LAG-3Ig)enhances immune responses and antitumor activity", J Transl Med, 8, pp.71~ (2010)
84. Nath PR, "CD47expression in natural killer cells regulates homeostasis and modulates immune response to Lymphocytic choriomeningitis virus", Front Immunol, 9, pp.2985~ (2018)
85. Nath PR, "Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment", Cancer Immunol Res, 7, pp.1547~1561 (2019)
86. Valipour B, "Cord blood stem cell derived CD16(+)NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47antibody", Life Sci, 242, pp.117223~ (2020)
87. Tsao LC, "CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis", JCI Insight, 4, pp.e131882~ (2019)
88. Allard B, "The ectonucleotidases CD39 and CD73 : novel checkpoint inhibitor targets", Immunol Rev, 276, pp.121~144 (2017)
89. Neo SY, "CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment", J Clin Invest, 130, pp.1185~1198 (2020)
90. Wang J, "NT5E", CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma, 2019, pp.8, 1526~
91. Chambers AM, "Immunometabolic dysfunction of natural killer cells mediated by the Hypoxia-CD73 axis in solid tumors", Front Mol Biosci, 6, pp.60~ (2019)
92. Zheng Y, "The roles of Siglec7and Siglec9 on natural killer cells in virus infection and tumour progression", J Immunol Res, 2020, pp.6243819~ (2020)
93. Hudak JE, "Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion", Nat Chem Biol, 10, pp.69~75 (2014)
94. Jandus C, "Interactions between Siglec-7", 9 receptors and ligands influence NK cell-dependent tumor immunosurveillance, 2014, pp.124, 1810~1820
95. Hernandez-Caselles T, "CD33(Siglec-3)Inhibitory function : role in the NKG2D", DAP10 activating pathway, 2019, pp.2019, 6032141~
96. Kohl U, "CAR T cells in trials : recent achievements and challenges that remain in the production of modified T cells for clinical applications", Hum Gene Ther, 29, pp.559~568 (2018)
97. Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
98. Ren J, "Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition", Clin Cancer Res, 23, pp.2255~2266 (2017)
99. Georgiadis C, "Long terminal repeat CRISPR-CAR-coupled"universal"T cells mediate potent anti-leukemic effects", Mol Ther, 26, pp.1215~1227 (2018)
100. Liu X, "CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells", Cell Res, 27, pp.154~157 (2017)
101. Shifrin N, "NK cell self tolerance, responsiveness and missing self recognition", Semin Immunol, 26, pp.138~144 (2014)
102. Cheng M, "NK cell-based immunotherapy for malignant diseases", Cell Mol Immunol, 10, pp.230~252 (2013)
103. Liu E, "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity", Leukemia, 32, pp.520~531 (2018)
104. Li Y, "Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity", Cell Stem Cell, 23, pp.181e185~192e185 (2018)
105. Rezvani K, "Engineering natural killer cells for cancer immunotherapy", Mol Ther, 25, pp.1769~1781 (2017)
106. Suck G, "NK-92 : an ’off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy", Cancer Immunol Immunother, 65, pp.485~492 (2016)
107. Karschnia P, "Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells", Blood, 133, pp.2212~2221 (2019)
108. Veluchamy JP, "The rise of allogeneic natural killer cells as a platform for cancer immunotherapy : recent innovations and future developments", Front Immunol, 8, pp.631~ (2017)
109. Moretta A, "Natural killer cells and dendritic cells : rendezvous in abused tissues", Nat Rev Immunol, 2, pp.957~964 (2002)
110. Wang WX, "CAR-NK for tumor immunotherapy : clinical transformation and future prospects", Cancer Letters, 472, pp.175~180 (2020)
111. Liu E, "Use of CARtransduced natural killer cells in CD19-positive lymphoid tumors", N Engl J Med, 382, pp.545~553 (2020)
112. Ruella M, "Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies", J Clin Invest, 126, pp.3814~3826 (2016)
113. Orlando EJ, "Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia", Nat Med, 24, pp.1504~1506 (2018)
114. Sayitoglu EC, "Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D", Front Immunol, 11, pp.40~ (2020)
115. Barrow AD, "The natural cytotoxicity receptors in health and disease", Front Immunol, 10, pp.909~ (2019)
116. Zhang C, "Chimeric antigen receptor-engineered NK-92 cells : an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity", Front Immunol, 8, pp.533~ (2017)
117. Dotti G, "Design and development of therapies using chimeric antigen receptor-expressing T cells", Immunol Rev, 257, pp.107~126 (2014)
118. Sadelain M, "The basic principles of chimeric antigen receptor design", Cancer Discov, 3, pp.388~398 (2013)
119. Chmielewski M, "T cell activation by antibody-like immunoreceptors : Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity", J Immunol, 173, pp.7647~7653 (2004)
120. Morgan RA, "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", Mol Ther, 18, pp.843~851 (2010)
121. Burger MC, "CAR-engineered NK cells for the treatment of glioblastoma : turning innate effectors into precision tools for cancer immunotherapy", Front Immunol, 10, pp.2683~ (2019)
122. Anderson P, "Cd3-negative natural-killer cells express Zeta-Tcr as part of a novel molecular-complex", Nature, 341, pp.159~162 (1989)
123. Kofler DM, "CD28costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation", Mol Ther, 19, pp.760~767 (2011)
124. Topfer K, "DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy", J Immunol, 194, pp.3201~3212 (2015)
125. Chang ZL, "CARs : synthetic immunoreceptors for cancer therapy and beyond", Trends Mol Med, 23, pp.430~450 (2017)
126. Alabanza L, "Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains", Mol Ther, 25, pp.2452~2465 (2017)
127. Brentjens RJ, "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias", Blood, 118, pp.4817~4828 (2011)
128. Long AH, "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors", Nat Med, 21, pp.581~590 (2015)
129. Salter AI, "Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function", Sci Signal, 11, pp.eaat6753~ (2018)
130. Kershaw MH, "A phase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer", Clin Cancer Res, 12, pp.6106~6115 (2006)
131. Sahm C, "Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumorspecific antigen receptor", Cancer Immunol Immunother, 61, pp.1451~1461 (2012)
132. Cichocki F, "GSK3inhibition drives maturation of NK cells and enhances their antitumor activity", Cancer Res, 77, pp.5664~5675 (2017)
133. Kagoya Y, "A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects", Nat Med, 24, pp.352~359 (2018)
134. Chmielewski M, "CAR T cells releasing IL-18 convert to T-Bet(high)FoxO1(low)effectors that exhibit augmented activity against advanced solid tumors", Cell Reports, 21, pp.3205~3219 (2017)
135. Chmielewski M, "TRUCKs : the fourth generation of CARs", Expert Opin Biol Ther, 15, pp.1145~1154 (2015)
136. Hurton LV, "Tethered IL-15 augments antitumor activity and promotes a stemcell memory subset in tumor-specific T cells", Proc Natl Acad Sci U S A, 113, pp.E7788~E7797 (2016)
137. Wang XM, "Inducible MyD88", CD40 synergizes with IL-15 to enhance antitumor efficacy of CARNK cells, 2020, pp.4, 1950~1964
138. Mitwasi N, "UniCAR-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells", Sci Rep, 10, pp.2141~ (2020)
139. Fabian KP, "PD-L1targeting high-affinity NK(t-haNK)cells induce direct antitumor effects and target suppressive MDSC populations", J Immunother Cancer, 8, pp.e000450~ (2020)
140. Chang YH, "A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells", Cancer Res, 73, pp.1777~1786 (2013)
141. Imamura M, "Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15", Blood, 124, pp.1081~1088 (2014)

관련 논문AI추천